EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma by Alexander J. J. Smits et al.
ORIGINAL PAPER
EGFR and KRAS mutations in lung carcinomas
in the Dutch population: increased EGFR mutation
frequency in malignant pleural effusion of lung
adenocarcinoma
Alexander J. J. Smits & J. Alain Kummer &
John W. J. Hinrichs & Gerarda J. M. Herder &
Karen C. Scheidel-Jacobse & N. Mehdi Jiwa &
T. Emiel G. Ruijter & Peet T. G. A. Nooijen &
Monica G. Looijen-Salamon &
Marjolijn J. L. Ligtenberg & Frederik B. Thunnissen &
Daniëlle A. M. Heideman & Roel A. de Weger &
Aryan Vink
Accepted: 19 March 2012 /Published online: 12 April 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Background Frequencies of EGFR and KRAS mutations in
non-small cell lung cancer (NSCLC) have predominantly
been determined in East Asian and North American popula-
tions, showing large differences between these populations.
The aim of the present study was to determine the frequency
of EGFR and KRAS mutations in NSCLC in the West Euro-
pean Dutch population in primary carcinomas and different
metastatic locations.
Methods EGFR (exons 19, 20 and 21) and KRAS (exons 2
and 3) mutation test results of NSCLC samples of patients in
13 hospitals were collected. The tests were performed on
paraffin-embedded tissue or cytological material of primary
and metastatic lung carcinomas.
Results EGFR mutations were detected in 71/778 (9.1 %)
tested patients; in 66/620 (10.6 %) adenocarcinomas. EGFR
mutations were significantly more often detected in female
than in male patients (13.4 % vs. 5.5 %, p<0.001). KRAS
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mutations were found in 277 out of 832 (33.3 %) tested
patients; in 244/662 (36.9 %) adenocarcinomas. A signifi-
cantly increased frequency of EGFR mutations was ob-
served in patients with malignant pleural/pericardial
effusions (26.5 %; odds ratio (OR) 2.80, 95 % confidence
interval (CI) 1.22–6.41), whereas the frequency of KRAS
mutations was significantly decreased (18.8 %; OR 0.35,
95 % CI 0.14–0.86).
Conclusions In the investigated Dutch cohort, patients with
malignant pleural/pericardial effusion of lung adenocarcino-
ma have an increased frequency of EGFR mutations. The
overall frequency of EGFR mutations in lung adenocarci-
nomas in this West European population is within the fre-
quency range of North American and South European
populations, whereas KRAS mutation frequency is higher
than in any population described to date.
Keywords Non-small cell lung cancer . Adenocarcinoma .
EGFR .KRAS . Metastasis . Pleural effusion
1 Introduction
Non-small-cell lung cancer (NSCLC) often presents at an
advanced stage with no options for curative treatment.
Response to chemotherapy is rather poor, resulting in a
median overall survival of approximately 1 year. New
therapies, targeting specific signaling pathways, have
been developed over the last years. These include the
small-molecule tyrosine kinase inhibitors (TKIs) erlotinib
and gefitinib, blocking signaling through the epidermal
growth factor receptor (EGFR). Treatment with these
TKIs seems to be especially effective in tumors with activat-
ing mutations in the EGFR gene, whereas tumors harboring
activating mutations in the KRAS gene do not respond to this
treatment [1].
The frequency of EGFR mutations has been studied most
extensively in East Asian populations, where it varies from
36.4 to 66.3 % in adenocarcinoma (ADC) [2, 3]. Studies in
North American and South European populations show
considerably lower numbers ranging from 6.0 to 14.0 %
[4, 5]. For KRAS the situation is reversed, with a low
mutation frequency of 2.3 to 9.4 % in East Asian [3, 6]
and a higher frequency of 11.7 to 31.0 % in North American
and South European populations [7, 8]. However, for the
West European population the frequency of EGFR and
KRAS mutations has not been studied in large numbers of
patients.
In East Asian and South European populations it has
been demonstrated that certain patient characteristics are
associated with an increased EGFR mutation rate. EGFR
mutations in these populations are associated with female
patients, patients who have never smoked and patients with
an adenocarcinoma [3, 9, 10]. In these studies EGFR muta-
tions are usually studied in tissue from the primary lung
tumor. Although the association between patient character-
istics and mutation status has been investigated extensively,
the association between different metastatic locations and
EGFR status has remained relatively underexplored.
The aim of the present study was to determine the frequency
of EGFR and KRASmutations in the Dutch population in both
primary NSCLCs and different metastatic locations.
2 Methods
2.1 Patients and tumor samples
We collected data of all NSCLC samples used for routine
diagnostic EGFR and KRAS mutation analysis from 13
hospitals in the Netherlands from January 2008 to April
2011. The participating hospitals were St. Antonius Hospital,
Nieuwegein; University Medical Center Utrecht; Rijnstate
Hospital, Arnhem; Medical Center Alkmaar; Jeroen Bosch
Hospital, ‘s Hertogenbosch; Radboud University Nijmegen
Medical Center; Zuwe Hofpoort Hospital, Woerden; Slinge-
land Hospital, Doetinchem; Gemini Hospital, Den Helder;
Hospital Gelderse Vallei, Ede; Hospital Bernhoven, Oss and
Veghel; Maas Hospital Pantein, Boxmeer; and Elkerliek
Hospital, Helmond. Mutation analysis was centrally per-
formed in four PathologyDepartments (St. Antonius Hospital,
Nieuwegein; University Medical Center Utrecht; VU Univer-
sity Medical Center, Amsterdam; and Radboud University
Nijmegen Medical Center).
The results were obtained using formalin-fixed paraffin-
embedded tissue or cytological slides of primary lung
tumors and metastases. The patients’ smoking status was
included for a subgroup of patients whose samples were
analyzed at St. Antonius Hospital, Nieuwegein and Univer-
sity Medical Center, Utrecht. Patients were categorized as
never smokers (<100 lifetime cigarettes), former smokers
(≥1 year since cessation), or current smokers (still smoking
or <1 year since cessation). When available, the number of
packyears was included in the smoking history.
2.2 Ethics statement
Specific approval of the ethics committee was not necessary
for this study, since all mutation analyses were part of the
routine diagnostic procedure and all patient and tumor char-
acteristics were collected anonymously.
2.3 EGFR and KRAS mutation analysis
Two methods were used for EGFR and KRAS mutation
analysis. In most cases mutation analysis was performed
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by polymerase chain reaction followed by sequencing of the
EGFR (exons 19, 20, and 21) and KRAS (exons 2 and 3)
genes, using GenBank Accession Numbers NM_005228.3
and NM_004985.3 as a reference. The samples of the patients
from the hospitals in Utrecht, Alkmaar, and ‘s Hertogenbosch
were tested using high resolution melting analysis, followed
by sequencing only if the obtained melting curve was abnor-
mal, as described previously [11].
2.4 Statistical analysis
Statistical calculations were performed using SPSS software
(version 15.0). Associations between EGFR and KRAS status
and patient and tumor characteristics were analyzed using the
Fisher’s exact test. Normal distribution of age and number of
packyears was tested using the Kolmogorov-Smirnov test and
means were compared using the Mann–Whitney test or the T
test when appropriate. Binary logistic regression analysis was
used to compare the mutation frequency of different metastatic
sites to the group of primary tumors. Odds ratio (OR) and
95 % confidence interval (CI) were calculated. In all tests,




EGFR mutation status was determined in 816 samples, 791 of
which had an interpretable result. The samples consisted of
655 cases of ADC, 42 cases of squamous cell carcinoma
(SCC), and 119 others (102 large cell carcinomas, 8 sarcoma-
toid carcinomas, 5 adenosquamous carcinomas, 4 unspeci-
fied). Of these samples, 462 were derived from primary
tumors and 342 from different metastatic sites. For 12 pleural
biopsies/excisions, distinction between a primary tumor and a
metastasis was not possible. The samples were derived from
803 individual patients, of whom there was an interpretable
result in 778 patients. For 13 patients the mutation status of
both their primary tumors and a metastasis was determined.
These patients were considered EGFR mutation positive if
either the primary tumor or the metastasis was tested positive.
EGFR mutations were detected in 71 (9.1 %) individual
patients, 66 of whom had a diagnosis of ADC (frequency in
ADC 10.6 %). The other 5 mutations were found in 3 large
cell carcinomas, one adenosquamous carcinoma, and one
sarcomatoid carcinoma (subtype spindle cell carcinoma).
EGFR mutations were significantly more often observed in
ADC than in SCC or other tumor types (10.6 %, 0 %, and
4.3 % respectively, p00.006) and more frequently in female
than in male patients (13.4 % vs. 5.5 %, p<0.001) (Table 1).
The smoking history could be obtained for 288 patients with a
known EGFRmutation status. The EGFRmutation frequency
was significantly higher in never smokers compared to former
and current smokers (48.3 % vs. 8.5 % vs. 4.9 % respectively,
p<0.001). Within the group of former and current smokers,
the average number of packyears smoking history was signif-
icantly lower in EGFR mutation positive compared to EGFR
mutation negative patients (23.6 vs. 35.6, P00.031).
Among the EGFRmutations, deletions in exon 19 were the
most common (39; 52.7 %), followed by the L858R point
Table 1 Frequency of EGFR and KRAS mutations
EGFR mutated N (%) EGFR wild
type N (%)
p-value KRAS mutated N (%) KRAS wild
type N (%)
p-value
Total 71 (9.1) 707 (90.9) 277 (33.3) 555 (66.7)
Mean age years±sem 61.6±1.28 62.7±0.39 0.347 61.1±0.63 62.8±0.45 0.014
Sex
Male 23 (5.5) 398 (94.5) <0.001 137 (30.6) 310 (69.4) 0.090
Female 48 (13.4) 309 (86.6) 140 (36.4) 245 (63.6)
Smoking history
Never 14 (48.3) 15 (51.7) <0.001 3 (12.0) 22 (88.0) 0.044
Former 10 (8.5) 107 (91.5) 37 (33.9) 72 (66.1)
Current 7 (4.9) 135 (95.1) 56 (36.6) 97 (63.4)
Mean no. of packyearsa 23.6 35.6 0.031 30.7 29.9 0.808
Histology
ADC 66 (10.6) 554 (89.4) 0.006 244 (36.9) 418 (63.1) <0.001
SCC 0 (0) 41 (100) 1 (2.5) 39 (97.5)
Other 5 (4.3) 112 (95.7) 32 (24.6) 98 (75.4)
sem standard error of the mean; ADC adenocarcinoma; SCC squamous cell carcinoma
a For former and current smokers only
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mutation in exon 21 (21; 28.4 %) (Fig. 1). Besides these
regular mutations, one insertion (V769-D770 ins ASV) and
four different point mutations in exon 20 (S768I (twice),
S768N, G779S, and H805Y), and four different point muta-
tions in exon 21 (R831H, V845A, D855N and L861Q (twice))
were found. Also, three (TKI resistant) T790M point mutations
in exon 20 were detected, all in combination with another
(activating) EGFR mutation (one deletion in exon 19 and
two L858R point mutations in exon 21). The single nucletoid
polymorphism A840T in exon 21 was detected twice.
3.2 KRAS mutations
KRAS mutation status was determined in 873 samples (699
ADC, 42 SCC, 132 others), 845 of which could be interpreted.
Of these samples, 497 were derived from primary tumors and
363 from different metastatic sites. For 13 pleural biopsies/
excisions, distinction between a primary tumor and a metas-
tasis was not possible. The samples were derived from 860
individual patients, of whom there was an interpretable result
in 832 patients. For 13 patients the mutation status of both
their primary tumor and a metastasis was determined. These
patients were considered KRAS mutation positive if either the
primary tumor or the metastasis was tested positive. KRAS
mutations were detected in 277 (33.3 %) patients, 244 of
whom had a diagnosis of ADC (frequency in ADC 36.9 %).
Like EGFR mutations, KRAS mutations were significantly
more common in ADC than in SCC or other tumor types
(36.9 %, 2.5 %, and 24.6 % respectively, p<0.001) and there
was a trend towards more mutations in female compared to
male patients (36.4 % vs. 30.6 %, p00.090), but this did not
reach statistical significance (Table 1). The smoking history
could be obtained for 287 patients with a known KRAS
mutation status. There was a lower KRAS mutation frequency
in never smokers compared to former and current smokers
(12.0 % vs. 33.9 % vs. 36.6 % respectively, p00.044). There
was no difference in average number of packyears between
KRASmutation positive and KRASmutation negative patients
(30.7 vs. 29.9, p00.808). The KRAS mutations consisted of
point mutations in codon 12 (239; 86.3 %), codon 13 (20;
7.2 %) and codon 61 (18; 6.5 %) (Fig. 1).
3.3 Combined EGFR and KRAS mutations
For 752 patients both the EGFR and KRAS mutation status
were determined. EGFR and KRAS mutations were mainly
found mutually exclusive. Only two cases (0.3 %) of com-
bined EGFR and KRAS mutations were detected: EGFR
exon 20 S768N combined with KRAS exon 2 G12A and
EGFR exon 20 G779S combined with KRAS exon 2 G12C.
These were both cases of ADC in males, detected in bron-
chial biopsies.
3.4 Primary carcinomas versus metastases
The difference in mutation frequency between primary tumors
and metastases was studied. Because nearly all EGFR and
KRAS mutations were found in ADC, we performed these
calculations for ADC only. Pleural biopsies and excisions
were excluded from these calculations, since discrimination
between outgrowth of a primary tumor or a metastasis was not
always feasible. The EGFR status was determined in 360
primary tumors and 261 metastatic sites, the KRAS status in
394 primary tumors and 268 metastatic sites. For EGFR
mutations, no statistically significant difference in frequency
in primary tumors compared tometastases (11.4 % vs. 10.0%,
p00.602) was observed (Table 2), whereas for KRAS the
mutation frequency was significantly higher in primary
tumors than in metastases (40.1 % vs. 31.3 %, p00.026)
(Table 3).
Next, we divided the metastasis locations in different
tissue types, using main categories with at least 10 samples
each. The categories were lymph node, pleural and pericar-
dial effusion, liver, brain, bone, soft tissue and others. The
results are summarized in Tables 2 and 3. Overall a signif-
icant difference between different categories was observed
Fig. 1 Distribution of EGFR (A) and KRAS (B) mutations. * All exon 20 T790M EGFR mutations were detected in combination with either an
exon 19 deletion or an exon 21 L858R mutation
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for the presence of both EGFR andKRASmutations (p00.034
and p00.017, respectively). Binary logistic regression analy-
sis was performed to test which category or categories was
responsible for this difference. Both for EGFR and KRAS the
category pleural and pericardial effusions was associated with
a difference in mutation frequency compared to primary
tumors (EGFR OR02.80 (95 % CI 1.22-6.41), p00.015;
KRAS OR00.35 (95 % CI 0.14–0.86), p00.022). The fre-
quency of EGFR mutations in this category was 26.5 %; the
frequency of KRAS mutations was 18.8 %. Also brain metas-
tases showed a trend towards an increase in EGFR mutation
frequency and a decrease in KRAS mutation frequency
(25.0 % and 9.1 %, respectively) compared to the group of
primary tumors, but this did not reach statistical significance.
The present study population contained 13 pairs of matched
primary tumors and metastases. There was discordance of the
EGFR and/or KRAS mutation status in 4 out of these 13
(30.8 %) pairs, leading to a clinically discordant mutation
status in 3/13 (23.1 %) pairs: one KRAS mutation was present
in the metastasis but not in the primary tumor; one EGFR
mutation was present in the metastasis but not in the primary
tumor, while this primary tumor showed a KRASmutation that
was not present in the metastasis; and one primary tumor
showed both a deletion in exon 19 and the T790M point
mutation in exon 20 of EGFR, whereas the metastasis only
showed the deletion in exon 19. In one pair the primary tumor
and the metastasis each contained a different KRAS mutation
(exon 1 G12Vand G12R, respectively).







p-value* OR   (95% CI) p-value** 
Primary tumors 41 (11.4) 319 (88.6) 
All metastases 26 (10.0) 235 ( 90.0) 
0.602a
Lymph node 10 (7.5) 123 (92.5) 0.63 (0.31-1.30) 0.214 
Pleural/pericardial 
effusion 9 (26.5) 25 (73.5) 2.80 (1.22 -6.41) 0.015 
Liver 1 (5.3) 18 (94.7) 0.43 (0.06-3.32) 0.420 
Brain 3 (25.0) 9 (75.0) 2.59 (0.68-9.97) 0.165 
Bone 2 (8.7) 21 (91.3) 0.74 (0.17-3.28) 0.693 
Soft tissue 0 (0) 18 (100) -b - 
Other 1 (4.5) 21 (95.5) 0.37 (0.05-2.83) 0.338 
OR odds ratio; CI confidence interval
*P-value calculated by Fisher’s exact test
**P-value calculated by binary logistic regression analysis
a Primary tumors vs. all metastases combined; p00.034 for primary tumors vs. different tumor locations separately
b Can not be calculated because 0 EGFR mutations were detected in this category






p-value* OR   (95% CI) p-value** 
Primary tumors 158 (40.1) 236 (59.9) 
All metastases 84 (31.3) 184 (68.7) 
0.026a 
Lymph node 44 (31.7) 95 (68.3) 0.69 (0.46-1.04) 0.078 
Pleural/pericardial 
effusion 6 (18.8) 26 (81.3) 0.35 (0.14 -0.86) 0.022 
Liver 5 (22.7) 17 (77.3) 0.44 (0.16-1.22) 0.113 
Brain 1 (9.1) 10 (90.9) 0.15 (0.02-1.18) 0.071 
Bone 7 (33.3) 14 (66.7) 0.75 (0.30-1.89) 0.538 
Soft tissue 8 (44.4) 10 (55.6) 1.20 (0.46-3.09) 0.714 
Other 13 (52.0) 12 (48.0) 1.62 (0.72-3.64) 0.244 
OR odds ratio; CI confidence interval
*P-value calculated by Fisher’s exact test
**P-value calculated by binary logistic regression analysis
a Primary tumors vs. all metastases combined; p00.017 for primary tumors vs. different tumor locations separately
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4 Discussion
To our best knowledge this is the first study showing an
association between EGFR mutation rate and metastatic loca-
tion in patients with lung adenocaricnoma in the European
population. We found an increased EGFRmutation frequency
(27 %) and a decreased KRAS mutation frequency (19 %) in
patients with malignant pleural or pericardial effusions. A
similar trend was present in patients with brain metastases,
although this did not reach statistical significance. These
results correspond with two studies from East Asia, showing
significantly higher EGFR mutation rates in tumors with
malignant pleural effusions compared to those without [12],
and a relatively high EGFR mutation rate in brain metastases
[13]. These observations are important for the treatment of
patients with metastasized ADC of the lung. In patients with
malignant pleural or pericardial effusion, the treating physi-
cian could make an extra effort to obtain tissue for mutation
analysis or, if no tissue can be obtained, a test treatment with
TKI could be considered. The genetic profile of a tumor
determines its biological behavior and the EGFR and KRAS
mutation status could very well influence the pattern of me-
tastasis formation, a topic that merits further investigation.
Several studies have shown discordance in the presence of
EGFR and KRAS mutations between primary tumors and
matched metastases [14, 15]. In the 13 pairs of primary tumors
and matched metastases in our cohort there were different
mutations in 4 out of 13 (31 %) pairs, leading to a clinically
different mutation status in 3/13 (23 %) pairs. In these latter
cases the difference in mutation status between primary tumor
and metastasis could have clinical implications in view of the
response to treatment with TKIs. We do not have information
concerning the treatment of these patients with TKIs or che-
motherapy between the times at which the primary tumor and
metastasis samples were obtained. Treatment could have
caused selection pressure, leading to a growth advantage for
certain clones, thus giving rise to a different mutation status. In
the process of metastasis formation, outgrowth of certain
clones of tumor cells can also take place without the influence
of selection pressure.
The overall frequency of EGFR and KRAS mutations has
mainly been studied in East Asian and North American and
to a lesser extent in South European populations, showing
large differences between these populations. This study is
the first to address this topic in a large West European
cohort. In adenocarcinomas, we found EGFR mutations in
11 % of cases. This is far below the 36–66 % reported for
East Asia [2, 3], but lies within the range of 6–24 % reported
for North America [4, 5], 6–16 % for Southern Europe [9,
16], and 11 % in a recent smaller North European (Norwe-
gian) study [17]. This similarity could be explained by the
fact that the ethnic background of our study population will
probably correspond closer to the North American and South
European than to the East Asian population, though environ-
mental influences may still differ between these populations.
Exon 18 of the EGFR gene was not included in the analysis,
because this exon was not routinely investigated in all partic-
ipating laboratories. This may have led to an underestimation
of the EGFRmutation frequency, although exon 18 mutations
have been reported to account for only a small minority of
total EGFR mutations [4, 18].
KRAS mutations were detected in 37 % of ADC, far above
the 2–9 % reported for East Asia [3, 6]. The KRAS mutation
frequency in ourWest European cohort is even higher than the
12–31 % and 11–29 % reported for North America [4, 8] and
Southern Europe [7, 9], respectively. The observed KRAS
mutation frequency is close to the 39 % reported in a Dutch
validation study for HRM that analyzed a small group of lung
cancer patients [19]. A possible partial explanation for the
observed difference could be the fact that in most studies only
point mutations in codons 12 and 13 were studied, which
make up over 90 % of KRAS mutations [20]. In addition to
codons 12 and 13, we also studied codon 61 and a substantial
7 % of mutations were detected in this codon, which would
have been missed if only the hotspots codons 12 and 13 had
been tested.
EGFR mutations were twice as often observed in female
compared to male patients (13 % vs. 6 %, p<0.001). This
observation confirms that the difference in EGFR mutation
frequency between male and female patients that previously
has been described in Asian and South European popula-
tions, is also present in the West European population [2, 3,
9, 16]. We found a trend towards more KRAS mutations in
female compared to male patients (36 % vs. 31 %), but this
did not reach statistical significance. Previous studies also
did not show a statistically significant correlation between
KRAS mutation status and sex, though some studies showed
a trend towards more mutations in males [6, 21]. However,
in these studies the total number of KRAS mutations was
very low as these were performed in East Asian populations.
The EGFR mutation frequency was over five times higher
in never smokers compared to former and current smokers.
This strong negative association with smoking history has also
been observed in Asian, North American, and South European
populations [2, 3, 5, 9, 16]. The association between presence
ofKRASmutations and smoking has also been reported before
[22].
Both EGFR and KRAS mutations were present more
commonly in ADC compared to SCC and other tumor types.
This observation confirms previous results [16].
The EGFRmutations consisted mainly of deletions in exon
19 and the L858R point mutation in exon 21. These two types
of mutations combined formed 81% of all EGFRmutations in
our cohort, which approximates the 85 to 90 % mentioned in
previous studies [23]. Possibly the proportion of these two
types of mutations is somewhat lower in the present study,
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because some of the other studies only investigated the more
common mutation sites. Besides two L861Q point mutations
in exon 21, known to be TKI-sensitive [23], we found 7
different more rare point mutations: S768I (twice), S768N,
G779S, and H805Y in exon 20 and R831H, V845A, and
D855N in exon 21. All of these rare point mutations have
been reported before [14, 23–27], except for the H805Y and
V845A mutations, though other mutations at the same posi-
tion have been reported [28, 29]. For all these point mutations,
the clinical significance and sensitivity to TKIs are unknown.
Three T790M point mutations in exon 20, known to
cause resistance to treatment with TKIs, were detected, all
in combination with an activating EGFR mutation (one
deletion in exon 19 and two L858R point mutations in exon
21). The T790M point mutation is considered to cause
secondary resistance to treatment with TKIs and thus is
expected to be present after treatment only [30], although
others report it to be present in tumors before treatment [31].
The insertion in exon 20 that was detected, has been
reported previously [3, 6]. This and other insertions in exon
20 have been associated with TKI resistance [23, 32].
EGFR and KRAS mutations are generally considered to be
mutually exclusive [2–4, 9], though there are some studies
showing combined EGFR and KRAS mutations [33]. We
found 2 cases of combined EGFR and KRAS mutations.
Interestingly, in both cases the EGFR mutation was a rare
point mutation (S768N and G779S) with unknown clinical
significance. Possibly these mutations do not cause constitu-
tional activation of EGFR and thus have no clinical signifi-
cance. This could also explain why they have often been
found in combination with known activating EGFR muta-
tions, as described previously [24, 26].
A limitation of the present study is the fact that it does not
provide a true cross-section of non-small cell lung carcinomas,
since most analyses were requested by the treating physician.
This introduces a selection bias towards more advanced dis-
ease stages, because the treating physician will generally not
request the analysis for patients who have been cured surgi-
cally. However, this corresponds to daily clinical practice, and
the population studied here, is the population that would
potentially benefit from treatment with TKIs, which still
makes the data relevant.
In conclusion, EGFR and KRAS mutation frequencies are
not evenly distributed among different metastatic sites, with a
relative increase in EGFR mutation frequency and a decrease
in KRAS mutation frequency in pleural and pericardial effu-
sions compared to primary tumors, which could have impli-
cations for patient management. In the West European Dutch
population the overall EGFR mutation frequency lies within
the range of frequencies described for North American and
South European populations. For KRAS the frequencies are
considerably higher than those described in any other popu-
lation studied to date. Both EGFR and KRAS mutations were
foundmore often in ADC than in other tumor types and EGFR
mutations were more common in females compared to males.
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